Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

被引：0
|
作者：
Kim A. Papp
Melinda Gooderham
Ignacio Dei-Cas
Adriana LopezTello
Juan C. Garcia-Rodriguez
Carmen Yris Taveras
Azucena Hernández Rousselin
Alberto Lavieri
Mónica Maiolino
Delfina Guadalupe Villanueva Quintero
Lenka Rihakova
Mariano Salibe
Wilfran Pertuz
机构：
[1] K Papp Clinical Research and Probity Medical Research,SKiN Centre for Dermatology and Probity Medical Research
[2] Peterborough and Queen’s University,HIGA Presidente Perón, Servicio de Dermatología, Facultad Medicina UBA
[3] Psoriasis BsAs,undefined
[4] NEKI Servicios Medicos,undefined
[5] Vicente Guerreo,undefined
[6] DermaAdvance Center,undefined
[7] Hospital Regional Universitario Jose Maria Cabral Y Baez,undefined
[8] Hospital Roosevelt,undefined
[9] Calzada Roosevelt,undefined
[10] Private Clinic,undefined
[11] Consultorios Médicos Dr Bouzo,undefined
[12] Grupo Clínico CATEI (Centro de Atención en Enfermedades Inflamatorias) Sociedad Civil,undefined
[13] Novartis Pharmaceuticals Canada Inc.,undefined
[14] Novartis Argentina S.A.,undefined
[15] Novartis Pharma Logistics,undefined
[16] Inc.,undefined
[17] Panama,undefined
来源：
Dermatology and Therapy | 2023年 / 13卷
关键词：
Latin America; Plaque psoriasis; PURE registry; Real-world; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：269 / 283
页数：14
相关论文
共 50 条
  • [21] Real world data with secukinumab for moderate-to-severe plaque psoriasis: Evaluation of safety, efficacy and drug survival in 50 patients
    Gkini, Maria-Angeliki
    Bewley, Anthony
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB114 - AB114
  • [22] Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea
    Kim, Byung Soo
    Kim, Dong Hyun
    Shin, Bong Seok
    Lee, Eun-So
    Jo, Seong Jin
    Bang, Chul Hwan
    Yun, Yeojun
    Choe, Yong Beom
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2024, 15
  • [23] The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
    April W. Armstrong
    Timothy Fitzgerald
    Robert R. McLean
    Amanda Teeple
    Jonathan P. Uy
    Mobolaji Olurinde
    Katelyn Rowland
    Lin Guo
    Ying Shan
    Kristina Callis Duffin
    Advances in Therapy, 2023, 40 : 2493 - 2508
  • [24] The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
    Armstrong, April W.
    Fitzgerald, Timothy
    McLean, Robert R.
    Teeple, Amanda
    Uy, Jonathan P.
    Olurinde, Mobolaji
    Rowland, Katelyn
    Guo, Lin
    Shan, Ying
    Callis Duffin, Kristina
    ADVANCES IN THERAPY, 2023, 40 (05) : 2493 - 2508
  • [25] Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
    Bucur, Stefana
    Serban, Elena-Daniela
    Ileanu, Bogdan Vasile
    Costache, Raluca Simona
    Nicolescu, Alin Codrut
    Constantin, Traian
    Costache, Daniel Octavian
    Constantin, Maria -Magdalena
    PSORIASIS-TARGETS AND THERAPY, 2024, 14 : 79 - 86
  • [26] Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety
    Asawanonda, Pravit
    Pattamadilok, Bensachee
    Chularojanamontri, Leena
    Chuamanochan, Mati
    Choonhakarn, Charoen
    Chakkavittumrong, Panlop
    Sangob, Naruemon
    Rajatanavin, Natta
    DERMATOLOGIC THERAPY, 2022, 35 (12)
  • [27] Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study
    Carpentieri, Antonio
    Mascia, Paola
    Fornaro, Marco
    Beylot-Barry, Marie
    Taieb, Alain
    Foti, Caterina
    Loconsole, Francesco
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [28] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
    Leonardi, C
    Goffe, B
    Sobell, J
    Caro, I
    Wang, X
    Papp, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
  • [29] Evaluation of effectiveness and safety in two optimization strategies with secukinumab in the treatment of moderate severe psoriasis
    Ruiz-Villaverde, R.
    Ruiz-Carrascosa, J. C.
    Cuenca-Barrales, C.
    Rodenas-Herranz, T.
    Linares-Gonzalez, L.
    Vega-Castillo, J. J.
    Aguayo-Carreras, P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB60 - AB60
  • [30] Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis
    Sacchelli, L.
    Patrizi, A.
    Loi, C.
    Bardazzi, F.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (07) : E243 - E244
12345